or Try an Advanced Search...

    Technical Analysis for PROK - ProKidney Corp.

    Grade Last Price % Change Price Change
    D 2.50 1.63% 0.04
    PROK closed up 1.63 percent on Monday, July 1, 2024, on 56 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Up
    Historical PROK trend table...
    Date Alert Name Type % Chg
    NR7 Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Up 3 Days in a Row Strength 0.00%
    Up 4 Days in a Row Strength 0.00%
    200 DMA Support Bullish 1.63%
    Pocket Pivot Bullish Swing Setup 1.63%
    Volume Surge Other 1.63%
    Wide Bands Range Expansion 1.63%
    Up 3 Days in a Row Strength 1.63%
    Older End-of-Day Signals for PROK ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 6 hours ago
    Rose Above Previous Day's High about 9 hours ago
    Up 3% about 9 hours ago
    60 Minute Opening Range Breakout about 9 hours ago
    Rose Above 10 DMA about 10 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    PROK Chart by TradingView
    Basic chart:

    Profile

    ProKidney, a pioneer in the treatment of chronic kidney disease (CKD) through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, REACT™ (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases drive meaningful improvement in kidney function. REACT™ has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program, which launched in January 2022.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Life Sciences Health Sciences Pharmacy Cell Therapy FDA Kidney Disease Regenerative Medicine Breakthrough Therapy Chronic Kidney Disease Regenerative Medicine Advanced Therapy

    Is PROK a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 17 ProKidney Announces the Closing of $140 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering, Including Exercise of Underwriters’ Option
    Jun 12 ProKidney surges 18% following pricing of upsized $130M stock offering
    Jun 12 ProKidney prices upsized stock offering to raise $130 million
    Jun 12 ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
    Jun 11 Why Calavo Growers Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
    Jun 10 ProKidney proposes $125M public offering of class A ordinary shares
    Jun 10 ProKidney Announces Proposed $125 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
    Jun 10 ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates
    May 29 ProKidney to Participate in the Jefferies Global Healthcare Conference
    May 23 ProKidney: Date Due In Several Days May Enhance Bull Thesis, But I'm Skeptical
    See more PROK news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 13.51
    52 Week Low 1.12
    Average Volume 1,001,692
    200-Day Moving Average 2.29
    50-Day Moving Average 2.93
    20-Day Moving Average 2.78
    10-Day Moving Average 2.49
    Average True Range 0.39
    RSI (14) 44.44
    ADX 17.22
    +DI 18.84
    -DI 20.47
    Chandelier Exit (Long, 3 ATRs) 3.11
    Chandelier Exit (Short, 3 ATRs) 3.22
    Upper Bollinger Bands 3.61
    Lower Bollinger Band 1.96
    Percent B (%b) 0.33
    BandWidth 59.39
    MACD Line -0.20
    MACD Signal Line -0.15
    MACD Histogram -0.0514
    Fundamentals Value
    Market Cap 169.71 Million
    Num Shares 67.9 Million
    EPS -0.58
    Price-to-Earnings (P/E) Ratio -4.31
    Price-to-Sales 0.00
    Price-to-Book 91.32
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.71
    Resistance 3 (R3) 2.71 2.65 2.68
    Resistance 2 (R2) 2.65 2.59 2.65 2.66
    Resistance 1 (R1) 2.57 2.56 2.61 2.57 2.65
    Pivot Point 2.51 2.51 2.53 2.51 2.51
    Support 1 (S1) 2.43 2.45 2.47 2.43 2.35
    Support 2 (S2) 2.37 2.42 2.37 2.34
    Support 3 (S3) 2.29 2.37 2.33
    Support 4 (S4) 2.29